Inhibitor of Aurora Kinase B Induces Differentially Cell Death and Polyploidy Via DNA Damage Response Pathways in Neurological Malignancy: Shedding New Light on the Challenge of Resistance to AZD1152-HQPA

Overview

Journal Mol Neurobiol

Specialties Molecular Biology
Neurology

Date 2015 Mar 11

PMID 25752998

Citations 7

Authors

Ali Zekri

Seyed H Ghaffari

Marjan Yaghmaie

Mehrdad Asghari Estiar

Kamran Alimoghaddam

Mohammad Hossein Modarressi

Ardeshir Ghavamzadeh

Affiliations

Soon will be listed here.

Abstract

Aurora kinase B (AURKB), a crucial regulator of malignant mitosis, is involved in chromosome segregation and cytokinesis. AZD1152-HQPA is a selective inhibitor for AURKB activity and currently bears clinical assessment for several malignancies. However, the effect of this drug still needs to be elucidated in neurological malignancies. In this study, we investigated the restrictive potentials of AZD1152-HQPA in U87MG and SK-N-MC. AZD1152-HQPA treatment resulted in growth arrest, modification of cell cycle, and inhibition of colony formation in both cell lines. Furthermore, lower concentrations of AZD1152-HQPA profoundly induced apoptosis in U87GM (p53/p73 wild type) cells in parallel with an upregulation of p53 and its target genes BAX, BAD, APAF1, and PUMA. But remarkably, SK-N-MC (p53/p73 double null) responded to AZD1152-HQPA at much higher concentrations with an upregulation of genes involved in cell cycle progression, induction of excessive endoreduplication, and polyploidy rather than apoptosis. Although SK-N-MC was resistant to AZD1152-HQPA, we did not find a mutation in the coding sequence of Aurora B gene or overexpressions of ABCG2 and ABCB1 as reported previously to be resistance mechanisms. However, our results suggest that p53/p73 status could be an important mechanism for the type of response and resistance of the tumor cells to AZD1152-HQPA. Collectively, inhibition of Aurora kinase B differentially induced cell death and polyploidy via DNA damage response pathways, depending on the status of p53/p73. We suggest p53/p73 could be a key regulator of sensitivity to AZD1152-HQPA and their status should be explored in clinical response to this ongoing drug in clinical trials.

Citing Articles

Phosphocatalytic Kinome Activity Profiling of Apoptotic and Ferroptotic Agents in Multiple Myeloma Cells.

Logie E, Perez Novo C, Driesen A, Van Vlierberghe P, Vanden Berghe W Int J Mol Sci. 2021; 22(23).

PMID: 34884535 PMC: 8657914. DOI: 10.3390/ijms222312731.

The p53 family member p73 in the regulation of cell stress response.

Rozenberg J, Zvereva S, Dalina A, Blatov I, Zubarev I, Luppov D Biol Direct. 2021; 16(1):23.

PMID: 34749806 PMC: 8577020. DOI: 10.1186/s13062-021-00307-5.

Viability fingerprint of glioblastoma cell lines: roles of mitotic, proliferative, and epigenetic targets.

Lavogina D, Laasfeld T, Vardja M, Lust H, Jaal J Sci Rep. 2021; 11(1):20338.

PMID: 34645858 PMC: 8514540. DOI: 10.1038/s41598-021-99630-0.

A Novel Ruthenium(II) Complex With Lapachol Induces G2/M Phase Arrest Through Aurora-B Kinase Down-Regulation and ROS-Mediated Apoptosis in Human Prostate Adenocarcinoma Cells.

De Grandis R, Oliveira K, Guedes A, Dos Santos P, Aissa A, Batista A Front Oncol. 2021; 11:682968.

PMID: 34249731 PMC: 8264259. DOI: 10.3389/fonc.2021.682968.

Purging human ovarian cortex of contaminating leukaemic cells by targeting the mitotic catastrophe signalling pathway.

Eijkenboom L, Mulder C, Van der Reijden B, Van Mello N, van Leersum J, Koorenhof-Scheele T J Assist Reprod Genet. 2021; 38(6):1571-1588.

PMID: 33725274 PMC: 8266964. DOI: 10.1007/s10815-021-02081-9.

References

Ulisse S, Delcros J, Baldini E, Toller M, Curcio F, Giacomelli L . Expression of Aurora kinases in human thyroid carcinoma cell lines and tissues. Int J Cancer. 2006; 119(2):275-82. DOI: 10.1002/ijc.21842. View

Talos F, Nemajerova A, Flores E, Petrenko O, Moll U . p73 suppresses polyploidy and aneuploidy in the absence of functional p53. Mol Cell. 2007; 27(4):647-59. DOI: 10.1016/j.molcel.2007.06.036. View

Bassing C, Alt F . The cellular response to general and programmed DNA double strand breaks. DNA Repair (Amst). 2004; 3(8-9):781-96. DOI: 10.1016/j.dnarep.2004.06.001. View

Van Brocklyn J, Wojton J, Meisen W, Kellough D, Ecsedy J, Kaur B . Aurora-A inhibition offers a novel therapy effective against intracranial glioblastoma. Cancer Res. 2014; 74(19):5364-70. PMC: 4528677. DOI: 10.1158/0008-5472.CAN-14-0386. View

Aihara A, Tanaka S, Yasen M, Matsumura S, Mitsunori Y, Murakata A . The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma. J Hepatol. 2009; 52(1):63-71. DOI: 10.1016/j.jhep.2009.10.013. View

Yu J, Zhang H, Gu J, Lin S, Li J, Lu W . Methylation profiles of thirty four promoter-CpG islands and concordant methylation behaviours of sixteen genes that may contribute to carcinogenesis of astrocytoma. BMC Cancer. 2004; 4:65. PMC: 520749. DOI: 10.1186/1471-2407-4-65. View

Talos F, Moll U . Role of the p53 family in stabilizing the genome and preventing polyploidization. Adv Exp Med Biol. 2010; 676:73-91. DOI: 10.1007/978-1-4419-6199-0_5. View

Tomasini R, Mak T, Melino G . The impact of p53 and p73 on aneuploidy and cancer. Trends Cell Biol. 2008; 18(5):244-52. DOI: 10.1016/j.tcb.2008.03.003. View

Gartel A, Tyner A . The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther. 2002; 1(8):639-49. View

10.

Zekri A, Ghaffari S, Ghanizadeh-Vesali S, Yaghmaie M, Salmaninejad A, Alimoghaddam K . AZD1152-HQPA induces growth arrest and apoptosis in androgen-dependent prostate cancer cell line (LNCaP) via producing aneugenic micronuclei and polyploidy. Tumour Biol. 2014; 36(2):623-32. DOI: 10.1007/s13277-014-2664-8. View

11.

Pluim D, Beijnen J, Schellens J, van Tellingen O . Simultaneous determination of AZD1152 (prodrug) and AZD1152-hydroxyquinazoline pyrazol anilide by reversed phase liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2009; 877(29):3549-55. DOI: 10.1016/j.jchromb.2009.08.035. View

12.

Walsby E, Walsh V, Pepper C, Burnett A, Mills K . Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts. Haematologica. 2008; 93(5):662-9. DOI: 10.3324/haematol.12148. View

13.

Freed-Pastor W, Prives C . Mutant p53: one name, many proteins. Genes Dev. 2012; 26(12):1268-86. PMC: 3387655. DOI: 10.1101/gad.190678.112. View

14.

Tao Y, Zhang P, Girdler F, Frascogna V, Castedo M, Bourhis J . Enhancement of radiation response in p53-deficient cancer cells by the Aurora-B kinase inhibitor AZD1152. Oncogene. 2007; 27(23):3244-55. DOI: 10.1038/sj.onc.1210990. View

15.

Michaelis M, Selt F, Rothweiler F, Loschmann N, Nusse B, Dirks W . Aurora kinases as targets in drug-resistant neuroblastoma cells. PLoS One. 2014; 9(9):e108758. PMC: 4182628. DOI: 10.1371/journal.pone.0108758. View

16.

Vitale I, Galluzzi L, Castedo M, Kroemer G . Mitotic catastrophe: a mechanism for avoiding genomic instability. Nat Rev Mol Cell Biol. 2011; 12(6):385-92. DOI: 10.1038/nrm3115. View

17.

Diaz R, Golbourn B, Shekarforoush M, Smith C, Rutka J . Aurora kinase B/C inhibition impairs malignant glioma growth in vivo. J Neurooncol. 2012; 108(3):349-60. DOI: 10.1007/s11060-012-0835-2. View

18.

Hontz A, Li S, Lingle W, Negron V, Bruzek A, Salisbury J . Aurora a and B overexpression and centrosome amplification in early estrogen-induced tumor foci in the Syrian hamster kidney: implications for chromosomal instability, aneuploidy, and neoplasia. Cancer Res. 2007; 67(7):2957-63. DOI: 10.1158/0008-5472.CAN-06-3296. View

19.

Schwartz G, Carvajal R, Midgley R, Rodig S, Stockman P, Ataman O . Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors. Invest New Drugs. 2012; 31(2):370-80. DOI: 10.1007/s10637-012-9825-7. View

20.

Stukenberg P . Triggering p53 after cytokinesis failure. J Cell Biol. 2004; 165(5):607-8. PMC: 2172375. DOI: 10.1083/jcb.200405089. View